Page 1206 - Basic _ Clinical Pharmacology ( PDFDrive )

1192 Index

Antitumor antibiotics Apremilast, 1079, 1079t Articaine, 460t, 469–470. See also
anthracyclines, 962t, 964–965 Aprepitant, 314, 317t, 1105, 1116t. See also Anesthetics, local
bleomycin, 962t, 965–966 Substance P, antagonists of Asacol, 1107, 1107f
mitomycin, 962t, 965 Apriso, 1107, 1107f Asbestos, 1016–1017
Antitumor monoclonal antibodies, Aprotinin, 308, 624 Ascariasis. See also Anthelmintic drugs
991–992 Aquaporin-2 (AQP2), 258, 258f albendazole for, 938–940, 939t
Anti-tumor necrosis factor (anti-TNF) Aquaretics, 267–268, 273t, 274t mebendazole for, 942
therapy, 1110–1112, 1111t, Aqueous diffusion, 7–8, 8f piperazine for, 944
1116t Arachidonic acid (AA), 321–322, 322f pyrantel pamoate for, 945–946
Antitussives dietary manipulation of metabolism of, Asenapine, 515
opioid, 570, 572t, 573t 337 Aspart, 768t. See also Insulin
OTC, 1124t prostanoid mediators from, 643, 646f Aspirin, 332, 645, 645t, 646f
Antivenoms, 991 Arcitumomab, 993 antiplatelet effects of, 619–620
Antiviral agents, 863–894. See also specific Area under the blood concentration-time drug interactions of, 1172t
types curve, 47, 47f dysmenorrhea treated with, 335
antihepatitis, 884t, 884–891 Area under the curve (AUC), 45 heart attack and stroke prevention using,
anti-influenza, 891–892 Argatroban, 617–618 335
antiretroviral, 870–884 Arginine vasopressin, 268. See Vasopressin; inflammation treated with, 336
entry inhibitors, 882–883 Vasopressin receptor agonists in OTC agents, 1129t
fundamentals of, 870 Aripiprazole. See also Antipsychotic agents overdose of, 1, 19
integrase strand transfer inhibitors, psychosis treated with, 514f, 515, 520t, peripheral artery disease and intermittent
883–884 528t claudication treated with, 209
nonnucleoside reverse transcriptase tics treated with, 506 poisoning management for, 1042–1043
inhibitors, 876–879 Aristolochic acid, 1133t Aspirin-exacerbated respiratory disease, 356
nucleoside and nucleotide reverse Arizona bark scorpion antivenom, 991 Astemizole, 284
transcriptase inhibitors, Aromatic hydrocarbons, 1009–1010 Asthma
870–876, 871t–872t Aromatic (4)-hydroxylation, 68 chronic obstructive pulmonary disorder
protease inhibitors, 879–882 Arrestins, 141 versus, 361
cytomegalovirus, 867–870 Arrhythmias, cardiac clinical features and severity of, 346–347
herpes simplex virus and varicella-zoster alcohol ingestion as cause of, 401 forms of, 347
virus, 864–867 beta-receptor antagonists for, 168 pathogenesis of, 347–348, 348f
history of, 863 impulse conduction disturbances, prevalence of, 346
imiquimod, 893 234–236 respiratory infection on, 346, 365
interferons, 892, 893t–894t impulse formation disturbances, 233f, subtypes of, 358
NS5A inhibitors, 888–889 233–234 Asthma drugs, 346–365, 362t–363t.
NS5B RNA polymerase inhibitors, 889 mechanisms of, 233–236 See also specific drugs
palivizumab, 893 molecular and genetic basis of, 234b, anti-IgE monoclonal antibodies, 357,
preparations available, 893t–894t 235f, 235t, 237f 362t
ribavirin, 893 pathophysiology of, 228, 229f antimuscarinics, 353–354, 354f
topical, 1074 treatment of asthma pathophysiology in, 347–348,
viral replication and, 863, 864f drugs in, 236–252 348f
Anxiety nonpharmacologic therapy in, 246b clinical pharmacology of, 358–361
benzodiazepines for, 544 Arsenic, 1025–1027 acute asthma management, 359
performance, b-receptor antagonists for, forms of intoxication with anti-IgE monoclonal antibody, 360
169 acute inorganic, 1026 anti-inflammatory therapies, other,
sedative-hypnotics for, 390–391 arsine gas, 1027 360
Apamin, 370t chronic inorganic, 1026–1027, 1027f bronchodilators, 359
Apis mellifera, 1133t history and epidemiology of, 1025 corticosteroids, 359
Apixaban, 617 pharmacodynamics of, 1025–1026 leukotriene antagonists, 360
Apo B-100 synthesis antisense inhibition, pharmacokinetics of, 1021t, 1025 muscarinic antagonists, 359
638 Artemether, 922–923 corticosteroids
Apocrine sweat glands, 148 Artemether-lumefantrine, 922t inhaled, 354–355, 362t
Apolipoprotein B-100 Artemisinins, 919f, 920t, 922–923 systemic, 354–355, 362t
description of, 626, 628f Arterial dilators, 225t cromolyn, 355–356, 362t
familial ligand-defective, 629t, 630 Artesunate, 922–923 future directions in, 358
Apomorphine (hydrochloride), 501, 508t Artesunate-amodiaquine, 922t, 922–923 leukotriene antagonists, 356f, 356–357,
Apraclonidine, 154t. See also Artesunate-sulfadoxine-pyrimethamine, 362t
Sympathomimetics 922t, 922–923 methylxanthines, 352f, 352–353, 362t